Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Leukemia-Lymphoma, Adult T-Cell 3Sezary Syndrome 2Recurrence 2Lymphoma, T-Cell, Peripheral 2Neoplasms 1Lymphoma, T-Cell 1Lymphoma 1Leukemia, T-Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × mogamulizumab × Clear all
NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
38 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Kyowa Kirin Co., Ltd.

Phase 2 Completed
1 enrolled 5 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡